CRL and MEDP Related Headlines
Go Back- Jefferies finds AI drives up to 50% cost cuts in drug development
- Barclays: Life science insiders sold $187M in stock during first quarter
- Life science tools Q3 preview: Barclays ups Charles River, downgrades Medpace
- Jefferies backs IQVIA and Charles River, cuts ICON on customer losses
